Антивирусные и противовоспалительные мишени апротинина: перспективы нового использования

Респираторные инфекции , патогенез , аэрозоль апротинина , вирус гриппа

1. Polgár L. The catalytic triad of serine peptidases. Cell Mol. Life Sci. 2005; 62 (19-20): 2161-2172.

2. Klenk H.D., Rott R., Orlich M., Blödorn J. Activation of influenza A viruses by trypsin treatment. Virology 1975; 68 (2): 426-439.

3. Choppin P.W., Scheid A., Mountcastle W.E. Proceedings: Paramyxoviruses, membranes, and persistent infections. Neurology (Minneap.) 1975; 25 (5): 494.

4. Chen J., Lee K.H., Steinhauer D.A. et al. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998; 95 (3): 409-417.

5. Chen Y., Shiota M., Ohuchi M. et al. Mast cell tryptase from pig lungs triggers infection by pneumotropic Sendai and influenza A viruses. Purification and characterization. Eur. J. Biochem. 2000; 267 (11): 3189-3197.

6. Murakami M., Towatari T., Ohuchi M. et al. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur. J. Biochem. 2001; 268 (10): 2847-2855.

7. Böttcher E., Matrosovich T., Beyerle M. et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006; 80 (19): 9896-9898.

8. Zhirnov O.P., Ikizler M.R., Wright P. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell-associated and sensitive to exogenous antiproteases. J. Virol. 2002; 76: 8682-8689.

9. Kido H., Chen Y., Murakami M. Cellular proteinases and viral infection: influenza virus, sendai virus, and HIV-1. In: Proteases of infectious agents. New York: Academic Press; 1999: 205-217.

10. Guo X.L., Li L., Wei D.Q. et al. Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin. Amino Acids 2008; 35 (2): 375-382.

11. Walker J.A., Sakaguchi T., Matsuda Y. et al. Location and character of the cellular enzyme that cleaves the hemagglutinin of a virulent avian influenza virus. Virology 1992; 190 (1): 278-287.

12. Walker J.A., Molloy S.S., Thomas G. et al. Sequence specificity of furin, a proprotein-processing endoprotease, for the hemagglutinin of a virulent avian influenza virus. J. Virol. 1994; 68 (2): 1213-1218.

13. Жирнов О.П., Овчаренко А.В., Букринская А.Г., Жданов В.М. Ингибиторы протеаз блокируют диссеминацию вируса гриппа в организме зараженных животных. Докл. АН СССР 1983; 270: 1483-1485.

14. Fritz H., Wunderer G. Biochemistry and application of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel-Forsch. / Drug Res. 1983; 33 (4): 479-494.

15. Goliando P.B., Ovcharenko A.V., Zhirnov O.P. Inhibition of the reproduction of the influenza B virus by aprotinin. Vopr. Virusol. 1992; 37 (3): 144-146.

16. Hosoya M., Matsuyama S., Baba M. et al. Effects of protease inhibitors on replication of various myxoviruses. Antimicrob. Agents Chemother. 1992; 36 (7): 1432-1436.

17. Жирнов О.П., Овчаренко А.В., Букринская А.Г. Расщепление гемагглютинина вируса гриппа под действием сывороточного плазмина в культуре клеток и ин виво. Вопр. вирусол. 1981; 6: 677-687.

18. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G.. Suppression of influenza virus replication in infected mice by protease inhibitors. J. Gen. Virol. 1984; 65: 191-196.

19. Жирнов О.П., Овчаренко А.В., Букринская А.Г. Подавление протеолитической активации миксовирусов в зараженных куриных эмбрионах с помощью апротинина. Вопр. вирусол. 1985; 2: 204-214.

20. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 1985; 66: 1633-1638.

21. Жирнов О.П., Овчаренко А.В., Букринская А.Г. Подавление ингибиторами протеаз репликации вируса гриппа в легких зараженных мышей. Вопр. вирусол. 1983; 3: 371-373.

22. Жирнов О.П., Киржнер Л.С., Овчаренко А.В., Малышев Н.А. Клиническая эффективность аэрозоля апротинина при гриппе и парагриппе. Вестн. РАМН 1996; 5: 26-31.

23. Zhirnov O.P., Kirzhner L.S., Ovcharenko A.V., Malyshev N.A. Aerosolized aprotinin is an effective drug against viral respiratory illness. Antiinfective Drug Chemother. 1996; 14: 209-216.

24. Жирнов О.П., Овчаренко А.В., Голяндо П.Б. и др. Антивирусный аэрозоль апротинина: Изучение местнораздражающего и аллергизирующего действия при ингаляционном введении. Антибиотики и химиотер. 1994; 39 (9-10): 54-59.

25. Жирнов О.П., Киржнер Л.С., Овчаренко А.В., Малышев Н.А. Патогенетическая терапия острых респираторных Заболеваний ингаляциями апротинина. Тер. арх. 1995; 6: 38-42.

26. Cheung C.Y., Poon L.L., Lau A.S. et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360 (9348): 1831-1837.

27. Atmar R.L., Guy E., Guntupalli K.K. et al. Respiratory tract viral infections in inner-city asthmatic adults. Arch. Intern. Med. 1998; 158 (22): 2453-2459.

28. Чучалин А.Г., Оспельникова Т.П., Осипова Г.Л. и др. Роль респираторных инфекций в обострениях бронхиальной астмы. Пульмонология 2007; 5: 9-15.

29. Seo S.H., Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 2002; 76 (3): 1071-1076.

30. Kiselev O.I., Vasil'eva I.A., Chepik E.B. Role of lymphokines in immune response in respiratory viral infections. Zh. Mikrobiol. Epidemiol. Immunobiol. 2002; 3: 84-92.

31. Schmitz N., Kurrer M., Bachmann M.F., Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 2005; 79 (10): 6441-6448.

32. Julkunen I., Melén K., Nyqvist M. et al. Inflammatory responses in influenza A virus infection. Vaccine 2000; 19 (suppl. 1): S32-S37.

33. Kawaguchi M., Kokubu F., Kuga H. et al. Influenza virus A stimulates expression of eotaxin by nasal epithelial cells. Clin. Exp. Allergy 2001; 31 (6): 873-880.

34. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007; 81 (1): 1-5.

35. Ronni T., Matikainen S., Sareneva T. et al. Regulation of IFN-alpha / beta, MxA, 2',5'-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells. J. Immunol. 1997; 158 (5): 2363-2374.

36. Jankowska R. Mechanisms of allergic inflammation in bronchial asthma. Centr. Eur J. Immunol. 2003; 28 (1): 36-40.

37. He S.H., Chen H.Q., Zheng J. Inhibition of tryptase and chymase induced nucleated cell infiltration by proteinase inhibitors. Acta Pharmacol. Sin. 2004; 25 (12): 1677-1684.

38. Smith T.J., Hougland M.W., Johnson D.A. Human lung tryptase: purification and characterization. J. Biol. Chem. 1984; 259 (17): 11046-11051.

39. Chakraborti S., Michael J.R., Chakraborti T. Role of an aprotinin-sensitive protease in protein kinase Calpha-mediated activation of cytosolic phospholipase A2 by calcium ionophore (A23187) in pulmonary endothelium. Cell Signal. 2004; 16 (6): 751-762.

40. Young R.E., Voisin M.B., Wang S. et al. Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice. Br. J. Pharmacol. 2007; 151 (5): 628-637.

41. Türköz A., Ciğli A., But K. et al. The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery. J. Cardiothorac. Vasc. Anesth. 2001; 15 (5): 603-610.

42. Churg A., Wang X., Wang R.D. et al. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am. J. Respir. Cell Mol. Biol. 2007; 37 (2): 144-151.

43. Hill G.E., Pohorecki R., Alonso A. et al. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth. Analg. 1996; 83 (4): 696-700.

44. Asimakopoulos G., Thompson R., Nourshargh S. et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J. Thorac. Cardiovasc. Surg. 2000; 120 (2): 361-369.

45. Bruda N.L., Hurlbert B.J., Hill G.E. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin. Sci. (Lond.) 1998; 94 (5): 505-509.

46. Аверьянов А.В., Поливанова А.Е. Нейтрофильная эластаза и болезни органов дыхания. Пульмонология 2006; 5: 74-79.

47. Чучалин А.Г. (ред.). Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA). М.: Изд-во «Атмосфера»; 2002.

48. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008; 8 (3): 183-192.

49. Pejler G., Abrink M., Ringvall M., Wernersson S. Mast cell proteases. Adv. Immunol. 2007; 95: 167-255.

50. Caughey G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol. Rev. 2007; 217: 141-154.

51. Kaplan A.P., Joseph K., Shibayama Y. et al. The intrinsic coagulation / kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv. Immunol. 1997; 66: 225-272.

52. Renné T., Gailani D. Role of factor XII in hemostasis and thrombosis: clinical implications. Expert Rev. Cardiovasc. Ther. 2007; 5 (4): 733-741.

53. Schousboe I. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. Biochem. Pharmacol. 2008; 75 (5): 1007-1013.

54. Bae S.W., Kim H.S., Cha Y.N. et al. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem. Biophys. Res. Commun. 2003; 306 (4): 981-987.

55. Venema R.C. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int. Immunopharmacol. 2002; 2 (13-14): 1755-1762.

56. Myöhänen H., Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol. Life Sci. 2004; 61 (22): 2840-2858.

57. Castellino F.J., Ploplis V.A. Structure and function of the plasminogen / plasmin system. Thromb. Haemost. 2005; 93 (4): 647-654.

58. Takizawa H. Bronchial epithelial cells in allergic reactions. Curr. Drug Targets Inflamm. Allergy 2005; 4 (3): 305-311.

59. Mukhopadhyay S., Hoidal J.R., Mukherjee T.K. Role of TNFalpha in pulmonary pathophysiology. Respir. Res. 2006; 7: 125.

60. Komarova Y.A., Mehta D., Malik A.B. Dual regulation of endothelial junctional permeability. Sci. STKE. 2007; 412: re8.

61. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 2007; 27 (1): 27-36.

62. Landis R.C. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol. Oncol. Clin. N. Am. 2007; 21 (1): 103-113.

63. Kobayashi Y. Neutrophil infiltration and chemokines. Crit. Rev. Immunol. 2006; 26 (4): 307-316.

64. Hassim Z., Maronese S.E., Kumar R.K. Injury to murine airway epithelial cells by pollen enzymes. Thorax 1998; 53 (5): 368-371.

65. Page K., Hughes V.S., Bennett G.W., Wong H.R. German cockroach proteases regulate matrix metalloproteinase-9 in human bronchial epithelial cells. Allergy 2006; 61 (8): 988-995.

66. Lee K.E., Kim J.W., Jeong K.Y. et al. Regulation of German cockroach extract-induced IL-8 expression in human airway epithelial cells. Clin. Exp. Allergy 2007; 37 (9): 1364-1373.

67. Platts-Mills T.A. Allergen avoidance in the treatment of asthma and rhinitis. N. Engl. J. Med. 2003; 349 (3): 207-208.

68. Pichavant M., Charbonnier A.S., Taront S. et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J. Allergy Clin. Immunol. 2005; 115 (4): 771-778.

69. Hughes V.S., Page K. German cockroach frass proteases cleave pro-matrix metalloproteinase-9. Exp. Lung Res. 2007; 33 (3-4): 135-150.

70. Mulgrew A.T., Taggart C.C., McElvaney N.G. Alpha-1-antitrypsin deficiency: current concepts. Lung 2007; 185 (4): 191-201.

71. Berninger R.W., Teixeira M.F. Alpha 1-antitrypsin: the effect of anticoagulants on the trypsin inhibitory capacity, concentration and phenotype. J. Clin. Chem. Clin. Biochem. 1985; 23 (5): 277-281.

72. Carrell R.W., Jeppsson J.O., Laurell C.B. et al. Structure and variation of human alpha 1-antitrypsin. Nature 1982; 298 (5872): 329-334.

73. Rasche B.., Marcic I., Ulmer W.T. Effect of the protease inhibitor aprotinin on pulmonary function and on the inhibitory activity of sputum in patients with chronic obstructive bronchitis. Arzneimittel Forsch. / Drug Research. 1975; 25 (1): 110-116

74. Stockley R.A. Bronchiectasis--new therapeutic approaches based on pathogenesis. Clin. Chest Med. 1987; 8 (3): 481-494.

75. Vogelmeier C., Biedermann T., Maier K. et al. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress. Eur. Respir. J. 1997; 10 (9): 2114-2119.

76. Meyer F.J., Wencker M., Teschler H. et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur. Respir. J. 1998; 12 (4): 996-997.

77. Ascenzi P., Bocedi A., Bolognesi M. et al. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr. Protein Pept. Sci. 2003; 4 (3): 231-251.

78. Planès C., Caughey G.H. Regulation of the epithelial Na+ channel by peptidases. Curr. Top. Dev. Biol. 2007; 78: 23-46.

79. Tong Z., Illek B., Bhagwandin V.J. et al. Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. Am. J. Physiol. Lung Cell Mol. Physiol. 2004; 287 (5): L928-L935.

80. Iwashita K., Kitamura K., Narikiyo T. et al. Inhibition of prostasin secretion by serine protease inhibitors in the kidney. J. Am. Soc. Nephrol. 2003; 14 (1): 11-16.

81. Shipway A., Danahay H., Williams J.A. et al. Biochemical characterization of prostasin, a channel activating protease. Biochem. Biophys. Res. Commun. 2004; 324 (2): 953-963.

82. Griese M., Latzin P., Kappler M. et al. Alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosispatients. Eur. Respir. J. 2007; 29 (2): 240-250.

83. Chokki M., Yamamura S., Eguchi H. et al. Human airway trypsin-like protease increases mucin gene expression in Airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2004; 30 (4): 470-478.

84. Voynow J.A., Fischer B.M., Zheng S. Proteases and cystic fibrosis. Int. J. Biochem. Cell Biol. 2008; 40 (6-7): 1238-1245.

85. Самсонова М.В., Черняева А.Л., Амелина Е.Л. Патология легких при муковисцидозе. Пульмонология 2006; 5: 113-117.

86. Капранов Н.И. Муковисцидоз - современное состояние проблемы. Пульмонология 2006; 5: 5-11.

87. Chand H.S., Foster D.C., Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb. Haemost. 2005; 94 (6): 1122-1130.

88. Sun Z., Lu W., Jiang A. et al. Expression, purification and characterization of aprotinin and human analogue of aprotinin. Protein Express. Purificat. 2009; 5: 34-40.

89. Sodha N.R., Boodhwani M., Bianchi C. et al. Aprotinin in cardiac surgery. Expert. Rev. Cardiovasc. Ther. 2006; 4 (2): 151-160.

90. Mangano D.T., Tudor I.C., Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. 2006; 354 (4): 353-365.

91. Beierlein W., Scheule A.M., Ziemer G. Anaphylactic aprotinin reaction. Ann. Thorac. Surg. 2000; 69 (4):1298.

92. Prieto García A., Villanueva A., Lain S., Baeza M.L. Fatal intraoperative anaphylaxis after aprotinin administration. J. Invest. Allergol. Clin. Immunol. 2008; 18 (2): 136.

93. Hogue C.W., London M.J. Aprotinin use during cardiac surgery: a new or continuing controversy? Anesth. Analg. 2006; 103 (5): 1067-1670.

94. Székely A., Sápi E., Breuer T. et al. Aprotinin and renal dysfunction after pediatric cardiac surgery. Paediatr. Anaesth. 2008; 18 (2): 151-159.

95. Furnary A.P., Wu Y., Hiratzka L.F. et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116 (suppl. II): II27-II33.